Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 114   

Articles published

NVO 56.35 +1.05 (1.90%)
price chart
New Deal Between Emisphere Technologies Inc. (EMIS) and Novo Nordisk A/S (ADR ...
On October 15, Emisphere Technologies Inc. (OTCMKTS:EMIS) announced an agreement with Novo Nordisk A/S (ADR) (NYSE:NVO) to develop and market oral formulations of four classes of the Danish company's investigational molecules targeting ...
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
HC Stocks Momentum: Novo Nordisk A/S (ADR) (NYSE:NVO), St. Jude Medical, Inc ...
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) ended Tuesday session in green amid volatile trading. The shares closed up +0.54 points or 1.05% at $52.15 with 1.65 million shares getting traded.
Shares of Novo Nordisk A/S (NYSE:NVO) Sees Large Outflow of Money  Market Digest
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Novo Nordisk to Submit Interim DEVOTE Data to the FDA  Zacks.com
Novo Nordisk A/S (NVO) Stares Down 50-Day Moving Average
Denmark-based drugmaker Novo Nordisk A/S (ADR) (NYSE:NVO) is just one of several pharmaceutical stocks making moves today, after Merck & Co.
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
Weekly Biotech Report Covering Novo Nordisk A/S (NYSE:NVO) Sanofi SA (NYSE:SNY ...
So this week we will skip forward another week and cover a big diabetes battle between Novo Nordisk A/S (NYSE:NVO) and Sanofi SA (NYSE:SNY).
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Novo Nordisk Follows Eli Lilly as Worthy Rival to Merck in Diabetes
Novo Nordisk A/S (ADR) (NYSE:NVO) jumped almost 8% in Friday's trade after it said that data from a major trial found its diabetes drug, Victoza, capable of significantly reducing risk of adverse cardiovascular events.